Antimicrobial Pharmacokinetics/dynamics Bedside ... - SWAB

More documents

Recommendations

Info

β-lactam specific pharmaco<strong>dynamics</strong>: T>MIC3210-1-2-3-4-5-6T > MIC (%)0 10 20 30 40 50 60 70 80 90Andes, Craig. Int J Antimicrob Agents 2002;19:261-8
More antibiotic specific: T > MIC for staticeffectT>MIC static effectEnterobacteriacieae% T > MICS. Pneumoniae% T > MICCeftriaxon 38 (34-42) 39 (37-41)Cefotaxime 38 (36-40) 38 (36-40)Ceftazidime 36 (27-42) 39 (35-42)Meropenem 22 (18-28) -Imipenem 24 (17-28) -Andes, Craig. Int J Antimicrob Agents 2002;19:261-8
Page 1 and 2: Antimicrobial Pharmacokinetics/dyna
Page 3 and 4: Inappropriate therapy and VAP morta
Page 5 and 6: Antibiotic dosing strategies in ren
Page 7 and 8: SepsisIncreased CardiacOutputLeaky
Page 9 and 10: Continuous Renal Replacement Therap
Page 11 and 12: Basic principlesExtracorporeal clea
Page 13 and 14: Efficacy and PharmacodynamicsDrug l
Page 15 and 16: Use of ciprofloxacin in the critica
Page 17 and 18: Quinolones: AUC/MIC > 125AUC above
Page 19 and 20: AUC 1-241ciprofloxacin 2 x 400 mg I
Page 21 and 22: Simulated fractional attainment of
Page 23: β-lactam static effects: streptoco
Page 27 and 28: Randomised, prospective, open singl
Page 29 and 30: Systematic review on clinical benef
Page 31 and 32: Total costs of intravenous antibiot
Page 33 and 34: The jury is still out on continuous
Page 35 and 36: Pk during CVVH various antibiotics3
Page 37 and 38: Risk of underdosingHydrophylic anti
Page 39: Thank you!Arthur van Zantenzantena@

Antimicrobial Pharmacokinetics/dynamics Bedside ... - SWAB

Create successful ePaper yourself

Delete template?

Save as template?